{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:06Z","timestamp":1791352206900,"version":"4.3.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Isolated seizures represent a distinct, rare, and underrecognized phenotype of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). In recent years, documentation of this phenotype has been limited to sporadic reports, with dedicated case series being extremely scarce. This study aimed to describe the clinical characteristics of isolated seizures in pediatric patients with MOGAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of pediatric patients diagnosed with MOG antibody-associated isolated seizures between January 2019 and January 2026. Clinical manifestations, brain magnetic resonance imaging (MRI) findings, laboratory data, treatment regimens, and clinical outcomes were systematically analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the cohort of 172 pediatric patients with seropositive MOG antibodies, 6 (3.4%) met the inclusion criteria for isolated seizures. The median age at onset was 7.5 years (range, 5\u20139 years), with a male-to-female ratio of 1:2. Clinically, 4 patients presented solely with epileptic seizures, while the other 2 patients had additional transient limb weakness or headache, respectively. Focal seizures were observed in 5 patients, including 3 with focal motor seizures; additionally, 2 cases experienced status epilepticus. No patients exhibited encephalopathy or focal neurological deficits. Four patients had peripheral blood leukocytosis (range, 11.9\u201326 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L), and five had elevated erythrocyte sedimentation rates (ESR; range, 22\u201343 mm\/h). All six patients showed cerebrospinal fluid (CSF) pleocytosis (41.1 \u00b1 20.4\/\u03bcL; range, 15\u201369\/\u03bcL) without detectable infectious pathogens. Abnormal electroencephalogram (EEG) findings, including abnormal background activity and focal slow waves, were identified in 3 patients. No cranial MRI abnormalities were detected in any patient. All patients received immunotherapy, with one patient additionally receiving anti-seizure medications (ASMs). At final follow-up, all patients had favorable outcomes, with no recurrence of seizures or subsequent demyelinating events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated isolated seizures is a rare and frequently underrecognized phenotype within the spectrum of MOGAD. For school-age children presenting with epileptic seizures, particularly focal motor seizures, along with elevated ESR and CSF pleocytosis, early testing for MOG antibody is recommended in the absence of clinical or radiological evidence of encephalitis or focal neurological deficits. Most patients achieve favorable clinical outcomes, which may be partially attributed to immunotherapy. However, the efficacy of immunotherapy in preventing seizure recurrence, subsequent demyelinating events, and subclinical radiological disease remains indeterminate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1934764","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:51Z","timestamp":1791348771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Myelin oligodendrocyte glycoprotein antibody-associated isolated seizures in children: a retrospective single-center case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Kang","family":"Liu","sequence":"first","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panhui","family":"Yu","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyao","family":"Ma","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubing","family":"Gong","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Lu","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[{"name":"First Department of Neurology, Hebei Children\u2019s Hospital","place":["Shijiazhuang, China"]},{"name":"Hebei Clinical Medicine Research Center for Children\u2019s Health and Diseases","place":["Shijiazhuang, China"]},{"name":"Hebei Provincial Key Laboratory for Pediatric Epilepsy and Neurological Disorders","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci Bull"},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10072-020-04828-1","article-title":"Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice","volume":"42","author":"Marchionatti","year":"2021","journal-title":"Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231156736","article-title":"Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey","volume":"29","author":"Nakamura","year":"2023","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102057","article-title":"Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis","volume":"42","author":"Shen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17315","article-title":"Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"63","author":"Li","year":"2022","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102011","article-title":"Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature","volume":"41","author":"Foiadelli","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518823486","article-title":"Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis","volume":"26","author":"Rossor","year":"2020","journal-title":"Mult Scler"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16571","article-title":"Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions","volume":"61","author":"Steriade","year":"2020","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106679","article-title":"Acute symptomatic seizures and epilepsy in pediatric patients with central nervous system inflammatory demyelinating diseases","volume":"103","author":"Li","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26502","article-title":"MOG and AQP4 antibodies among children with multiple sclerosis and controls","volume":"93","author":"Gaudioso","year":"2023","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ana.26549","article-title":"Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"93","author":"Valencia-Sanchez","year":"2023","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17424","article-title":"Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"63","author":"Montalvo","year":"2022","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012465","article-title":"Clinical course and features of seizures associated with LGI1-antibody encephalitis","volume":"97","author":"Smith","year":"2021","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17164","article-title":"CASPR2-IgG-associated autoimmune seizures","volume":"63","author":"Garrido Sanabria","year":"2022","journal-title":"Epilepsia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03058-x","article-title":"Less common phenotypes of myelin oligodendrocyte glycoprotein antibody-related diseases in children deserve more attention","volume":"96","author":"Wang","year":"2024","journal-title":"Pediatr Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S444853","article-title":"Clinical features of patients with myelin oligodendrocyte glycoprotein antibody-associated disease and isolated seizure symptoms","volume":"16","author":"Yang","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1515\/revneuro-2019-0020","article-title":"Perineuronal oligodendrocytes in health and disease: the journey so far","volume":"31","author":"Bernstein","year":"2019","journal-title":"Rev Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102168","article-title":"Improvement in recurrent anti-myelin oligodendrocyte glycoprotein antibody - positive cerebral cortical encephalitis not requiring anti - inflammatory therapy following the decrease in cytokine\/chemokine levels","volume":"43","author":"Takamatsu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20250112-00023","article-title":"Chinese guidelines for diagnosis and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (2025 edition)","volume":"58","author":"Shi","year":"2025","journal-title":"Chin J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2026.1746963","article-title":"Seizures as the initial manifestation: characterizing the adult phenotype of MOG antibody-associated disease","volume":"17","author":"Cao","year":"2026","journal-title":"Front Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2016.09.038","article-title":"Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice","volume":"1652","author":"Itoh","year":"2016","journal-title":"Brain Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12784","article-title":"The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1\u03b2 and TNF-\u03b1 expression in rat hippocampus","volume":"130","author":"G\u00f3mez","year":"2014","journal-title":"J Neurochem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:53Z","timestamp":1791348773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1934764"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1934764","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1934764"}}